Shared on08 Aug 25Fair value Decreased 3.50%
The modest reduction in PROCEPT BioRobotics’ consensus price target to $65.75 reflects a slight downward revision in the company’s future P/E multiple, while profitability remains stable. What's in the News Raised full-year 2025 revenue guidance to $325.5 million, representing 45% year-over-year growth; projected net loss for 2025 is $83.5 million.
Shared on24 Apr 25Fair value Decreased 0.53%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25Fair value Decreased 3.18%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Increased 9.95%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25Fair value Increased 23%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.